WO2019000147A1 - Arn tud inhibant efficacement l'expression des mir-148a, mir-152 et mir-185 humains et son utilisation - Google Patents
Arn tud inhibant efficacement l'expression des mir-148a, mir-152 et mir-185 humains et son utilisation Download PDFInfo
- Publication number
- WO2019000147A1 WO2019000147A1 PCT/CN2017/089927 CN2017089927W WO2019000147A1 WO 2019000147 A1 WO2019000147 A1 WO 2019000147A1 CN 2017089927 W CN2017089927 W CN 2017089927W WO 2019000147 A1 WO2019000147 A1 WO 2019000147A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mir
- tud
- vector
- pglv3
- preparation
- Prior art date
Links
- 108091027034 miR-148a stem-loop Proteins 0.000 title claims abstract description 36
- 108091037426 miR-152 stem-loop Proteins 0.000 title claims abstract description 36
- 108091047758 miR-185 stem-loop Proteins 0.000 title claims abstract description 34
- 230000014509 gene expression Effects 0.000 title claims abstract description 33
- 230000002401 inhibitory effect Effects 0.000 title description 7
- 239000013598 vector Substances 0.000 claims abstract description 32
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 37
- 230000000692 anti-sense effect Effects 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 9
- 108091081021 Sense strand Proteins 0.000 claims description 7
- 230000029087 digestion Effects 0.000 claims description 7
- 108020004414 DNA Proteins 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000013605 shuttle vector Substances 0.000 claims description 5
- 238000000137 annealing Methods 0.000 claims description 4
- 238000013461 design Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000003389 potentiating effect Effects 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 27
- 239000002679 microRNA Substances 0.000 description 25
- 108091070501 miRNA Proteins 0.000 description 14
- 108700011259 MicroRNAs Proteins 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 241000700605 Viruses Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 230000011987 methylation Effects 0.000 description 4
- 238000007069 methylation reaction Methods 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000003556 assay Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 108091068997 Homo sapiens miR-152 stem-loop Proteins 0.000 description 1
- 108091068954 Homo sapiens miR-185 stem-loop Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091030146 MiRBase Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 108091028606 miR-1 stem-loop Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 208000029387 trophoblastic neoplasm Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
Definitions
- the present invention relates to a Tud
- RNA in particular, relates to a Tud RNA effective for inhibiting the expression of human miR-148a, miR-152 and miR-185 and its use.
- MicroRNAs are a class of endogenous, non-coding RNAs found in eukaryotes, typically between 22 and 25 nt in size. miRNAs are widely distributed in plants, animals, and multicellular organisms, and can Play an important regulatory role, and in the study of human miRNAs, it is found that the expression of miRNA in normal tissues and tumor tissues is significantly different, some miRNAs are lowly expressed in tumor tissues, and some are highly expressed in tumor tissues. This suggests that miRNAs play a crucial role in tumorigenesis.
- miR-148a is a microRNA that has been studied more in recent years. It is reported that miR-148a is closely related to exogenous substance metabolism, apoptosis, occurrence, development and epigenetics of various cancers; miR-1 52 is a multifunctional miRNA, and the study found that miR- 152 is associated with methylation, such as methyltransferase DNMT1 content and enzyme activity, miR-152 can be methylated by endometrial cancer DNA into a silent gene, and it is associated with the development of various cancers, it It is a tumor suppressor microRNA, which is associated with many diseases such as preeclampsia, trophoblastic tumor, bladder cancer, gastrointestinal cancer, ovarian cancer, etc.
- miR-185 is a 22 nt miRNA located at human chromosome 22ql l.21, It plays an important role as a tumor suppressor gene in the development and invasion of tumors such as colon cancer, gastric cancer, esophageal cancer, lung cancer, and liver cancer. In addition, it is a methylation-related tumor suppressor miRNA that can directly target DNMT1. Expression affects the level of methylation in the whole genome, which in turn regulates the methylation status of certain genes and affects gene expression. By controlling the expression of miR-148a, miR-152 and miR-185, the synergy with other drugs can provide new epigenetic ideas for the treatment of cancer.
- Tough Decoy RNA is a novel miRNA-inhibiting miRNA that inhibits miRNA by introducing double-stranded RNA to target miRNAs. Because the inserted RNA is double-stranded and has a secondary structure of stem-loops, it is resistant to intracellular nuclease degradation and inhibits miRNAs in a long-term, stable, and efficient manner.
- the primary object of the present invention is to overcome the shortcomings and deficiencies of the prior art and to provide an effective suppression of human miR-
- Tud RNA expressed by 148a, miR-152 and miR-185 Tud RNA expressed by 148a, miR-152 and miR-185.
- Another object of the present invention is to provide the above-described use of Tud RNA which effectively inhibits the expression of human miR-148a, miR-152 and miR-185.
- a further object of the present invention is to provide a recombinant vector comprising the above Tud RNA.
- a Tud RNA which effectively inhibits the expression of human miR-148a, miR-152 and miR-185, and the DNA sequence encoding the Tud RNA which inhibits the expression of human miR-148a, miR-152 and miR-185 is as follows Show:
- Tud RNA which is effective for inhibiting the expression of human miR-148a, miR-152 and miR-185
- the application comprising constructing the Tud RNA on a lentiviral vector to obtain the Tud RNA containing the Tud RNA Recombinant vector; will contain the Tud
- the recombinant vector of RNA acts on 16HBE cells to inhibit the expression of miR-148a, miR-152 and miR-185;
- the lentiviral vector is a pGLV3/Hl/GFP+Puro (pGLV3) lentiviral shuttle vector
- the preparation method of the recombinant vector containing the Tud RNA comprises the following steps: (1) Designing a DNA sequence ⁇
- Tud-148a-152-185 antisense strand [0020] Tud-148a-152-185 antisense strand:
- the 5' end of the sense strand template is added with GATCC, which is complementary to the sticky end formed by BamHI digestion; the AATTC is added to the 5' end of the antisense strand template, which is complementary to the sticky end formed by EcoRI digestion;
- the Tud RNA of the present invention which inhibits the expression of human miR-148a, miR-152 and miR-185 is effective for inhibiting the expression of human miR-148a, miR-152 and miR-185.
- the Tud RNA, which inhibits the expression of human miR-148a, miR-152 and mi R-185 is constructed on a lentiviral vector, and is effective not only for dividing and non-dividing cells, but also for in vivo and in vitro studies.
- FIG. 1 is a structural diagram of a pGLV3 vector
- FIG. 2 is a miRNA expression level of each group of cells, wherein, a.
- miR-148a Expression of miR-148a, b. expression of miR-152, c. expression of miR-185.
- TuD RNA oligonucleosides targeting miR-148a, miR-152 and miR-185 were designed based on the sequence information of miR-148a, miR-152 and miR-185 provided in the TuD RNA design sequence and miRBase.
- Tud-148a-152-185 antisense strand [0035] Tud-148a-152-185 antisense strand:
- the 5' end of the sense strand template is added with GATCC, which is complementary to the sticky end formed by BamHI digestion; the AATTC is added to the 5' end of the antisense strand template, which is complementary to the sticky end formed by EcoRI digestion.
- the pGLV3 vector (Gimma Gene Co., Ltd.) was digested with BamH I and EcoR I, and the vector was linearized.
- the conditions of the digestion were as follows: pGLV3 vector (10 ⁇ , BamH I) Dicer (5 L, Fermentas), EcoR I endonuclease (5 L, Fermentas), FastDigest buffer (8 (VL, TOYOBO) were mixed, placed at 37 ° C for 1 hour, using a gel back kit ( Axygen) recovered the linear vector fragment and diluted its concentration to 50 ng ⁇ L.
- the plasmid was purified and verified by sequencing to prepare a recombinant plasmid pGLV3-Tud-148a-152-185.
- the recombinant vector pGLV3-Tud-148a-152-185 was co-transfected into packaging cells pGag/Pol, pRev, pVSV-G to 293T cells, and the culture supernatant was collected to obtain virus particles containing the desired Tud RNA. can be use on Transfect the target cells.
- 16HBE cells were seeded in 6-well plates, 1000000 cells per well, and the cell density was about 50% after 12 hours.
- the virus solution was taken separately, and the virus was diluted 10 times with DMEM complete medium, and then polyglycolamine was added.
- the medium in the 6-well plate was removed, and the virus-containing DMEM complete medium (containing 10% fetal bovine serum) was added. After 24 hours, the virus-containing DMEM complete medium was discarded, and the fresh DMEM complete medium was replaced. After 24 hours, 0.5 was used.
- the cells were screened at a g/ml concentration of puromycin. After 10 days of screening, the medium was changed once every 3 days, and the concentration of puromycin was continuously increased to 1.0 g/ml.
- the cell line obtained by screening was named TuD-148a-152-185 cell line.
- TuD-148a-152-185 cells were inoculated into 6-well plates (about 300,000 per well), and the cells were cultured for about 24 hours to a degree of fusion of 80%.
- the miRNAs of these cells were extracted using the miRcute miRNA extraction and isolation kit, followed by S-Poly(T) hsa-miR-148a qPCR-assay primer
- the set kit reverse-transcribes and tails the miRNA to obtain the corresponding cDNA.
- the cDNA of each of the two cells was used as a template, and the expression levels of miR-148a, miR-152 and miR-185 were detected by real-time PCR.
- the experiment was repeated 3 times, and 3 parallel samples were set per well, with snord 44 as the internal reference. .
- Fig. 2 it was found that the expression level of miR-148a with TuD-148a-152-185 cells was 60% lower than that of 16HBE cells, and the expression level of mi R-152 was 62% lower than that of 16HBE cells, miR-185 The expression level is 59% lower than that of 16HBE cells.
- the difference was statistically significant (/? ⁇ 0.01), indicating that the TuD-148a-152-185 cell line was successfully constructed.
- the Tud RNA of the present invention which inhibits the expression of human miR-148a, miR-152 and miR-185 is effective for inhibiting the expression of human miR-148a, miR-152 and miR-185.
- the Tud RNA, which inhibits the expression of human miR-148a, miR-152 and mi R-185 is constructed on a lentiviral vector, and is effective not only for dividing and non-dividing cells, but also for in vivo and in vitro studies.
Landscapes
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne un ARN TuD et son utilisation. L'ARN TuD peut inhiber efficacement l'expression des miR-148a, miR-152 et miR-185 humains. La séquence d'ADN codant pour l'ARN TuD est telle que représentée ci-dessous : 5'-ggcgctaggatcatcaactccccgaccgaaatctaggagaccagcaaagtcacgtactatctgtcttgaacccaaagtcacgtgatgatcttcttgaaacacaagtattctggtcacagaatacaactccccgaccgaaatctaggagaccagcaaagtcacgtactatctgtcttgaacccaaagtcacgtgatgatcttcttgaaacacaagatgatcctagcgccaccttttt-3'. L'utilisation de l'ARN TuD consiste à construire l'ARN TuD sur un vecteur lentiviral pour obtenir un vecteur recombiné; et à appliquer le vecteur recombiné aux cellules humaines pour inhiber l'expression des miR-148a, miR-152 et miR-185 humains.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2017/089927 WO2019000147A1 (fr) | 2017-06-26 | 2017-06-26 | Arn tud inhibant efficacement l'expression des mir-148a, mir-152 et mir-185 humains et son utilisation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2017/089927 WO2019000147A1 (fr) | 2017-06-26 | 2017-06-26 | Arn tud inhibant efficacement l'expression des mir-148a, mir-152 et mir-185 humains et son utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2019000147A1 true WO2019000147A1 (fr) | 2019-01-03 |
Family
ID=64741974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2017/089927 WO2019000147A1 (fr) | 2017-06-26 | 2017-06-26 | Arn tud inhibant efficacement l'expression des mir-148a, mir-152 et mir-185 humains et son utilisation |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2019000147A1 (fr) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010138263A2 (fr) * | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Nouveaux virus adéno-associés (aav) et leurs utilisations |
| CN102851291A (zh) * | 2006-04-03 | 2013-01-02 | 桑塔里斯制药公司 | 包含抗微小rna 反义寡核苷酸的药物组合物 |
| CN104357451A (zh) * | 2014-12-02 | 2015-02-18 | 广州市番禺区中心医院 | 针对dd3基因的小干扰rna及其表达载体构建与应用 |
-
2017
- 2017-06-26 WO PCT/CN2017/089927 patent/WO2019000147A1/fr active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102851291A (zh) * | 2006-04-03 | 2013-01-02 | 桑塔里斯制药公司 | 包含抗微小rna 反义寡核苷酸的药物组合物 |
| WO2010138263A2 (fr) * | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Nouveaux virus adéno-associés (aav) et leurs utilisations |
| CN104357451A (zh) * | 2014-12-02 | 2015-02-18 | 广州市番禺区中心医院 | 针对dd3基因的小干扰rna及其表达载体构建与应用 |
Non-Patent Citations (1)
| Title |
|---|
| SU, QUANQIU ET AL.: "The Research Progress of miR-185 in Tumor", JOURNAL OF MODERN MEDICINE & HEALTH, 15 February 2015 (2015-02-15), pages 380 - 383, ISSN: 1009-5519 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2925866B1 (fr) | Arn circulaire destiné à l'inhibition de micro-arn | |
| Liu et al. | Long non-coding RNA HNF1A-AS1 functioned as an oncogene and autophagy promoter in hepatocellular carcinoma through sponging hsa-miR-30b-5p | |
| EP3222723B1 (fr) | Développement de médicaments et vaccins universels contre le cancer | |
| CN105132424A (zh) | microRNA抑制剂、microRNA抑制剂表达载体及其构建方法和应用 | |
| US20110224284A1 (en) | Putative tumor suppressor microrna-101 modulates the cancer epigenome by repressing the polycomb group protein ezh2 | |
| WO2019000147A1 (fr) | Arn tud inhibant efficacement l'expression des mir-148a, mir-152 et mir-185 humains et son utilisation | |
| Magnani et al. | UHRF1 regulates CDH1 via promoter associated non-coding RNAs in prostate cancer cells | |
| JP2025513932A (ja) | Ｌｍｎａ変異キャリアのための治療における使用のためのアンチセンス核酸 | |
| WO2019033248A1 (fr) | Arn tud inhibant l'expression des mir-148a, mir-152 et mir-424 humains et son utilisation | |
| WO2019036871A1 (fr) | Arn tud pour l'inactivation spécifique des expressions de mir-148a, mir-185 et mi-424 d'êtres humains, et applications associées | |
| WO2019033246A1 (fr) | Arn tud pour la co-invalidation génique de trois miarn et utilisation associée | |
| WO2017214952A1 (fr) | Construction et application d'un vecteur lentiviral pour l'inhibition spécifique de l'expression de l'arnmi-185 humain | |
| CN103333893A (zh) | 一种抑制人口腔癌细胞PRPS2表达的shRNA及其载体的构建和应用 | |
| WO2019052000A1 (fr) | Miarn ciblant la voie de signalisation stat3, sa méthode de préparation et son application | |
| WO2018165929A1 (fr) | Vecteur d'expression inhibant le micro-arn double brin, son procédé de mise au point et son application | |
| WO2017214948A1 (fr) | Construction et application d'un vecteur lentiviral pour l'inhibition de l'expression de l'arnmi-148a humain | |
| CN110964727A (zh) | 特异抑制c-myc基因表达的shRNA慢病毒表达载体构建方法与应用 | |
| WO2017219166A1 (fr) | Vecteur lentiviral pour l'inhibition simultanée de l'expression de deux miarn, et application associée | |
| WO2017214951A1 (fr) | Construction et application d'un vecteur lentiviral pour l'inhibition de l'expression de l'arnmi-152 humain | |
| WO2023086026A2 (fr) | Procédé et composition pour inhiber l'activité de la télomérase | |
| WO2017214949A1 (fr) | Construction et application d'un vecteur lentiviral pour l'inhibition de l'expression d'arnmi-29a | |
| WO2018170751A1 (fr) | Arn tud destiné à antagoniser l'expression d'un micro-arn, et son application | |
| WO2017214950A1 (fr) | Construction et application d'un vecteur lentiviral pour l'inhibition de l'expression de l'arnmi-140 humain | |
| WO2018170758A1 (fr) | Adénovirus ad-140-148a-152-tud recombinant, et construction et application de celui-ci | |
| WO2018170650A1 (fr) | Arn tud pour antagoniser des expressions de microarn-29a, mir-140 et mir-148 humains, et son application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17916297 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 17916297 Country of ref document: EP Kind code of ref document: A1 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 17916297 Country of ref document: EP Kind code of ref document: A1 |